- Category
- Medium (2024-25)
- Udyam number
- UDYAM-GJ-24-0002899

About Mercury Laboratories Limited
Data last updated:
Mercury Laboratories Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 12 February 1982 and has been in existence for over 44 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L74239MH1982PLC026341. Its GSTIN is 27AAACM0414D2Z5 (Maharashtra). The company holds 10 GST registrations, of which 8 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 538964.
The company has an authorised share capital of ₹2.5 Cr and a paid-up capital of ₹1.2 Cr. It was formerly known as Mercury Laboratories Private Limited. It is led by directors including Rajendrakumar Ramanlal Shah (Managing Director) and Paresh Jagdishbhai Mistry.
Its last annual general meeting (AGM) was held on 13 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Shreeji Mang Idas Marketprincess Street, Mumbai, Maharashtra, India – 400002.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹75.94 Cr, a growth of 1.1% compared to the previous year. For the same year it recorded a net profit of ₹5.14 Cr (net margin 6.8%) and EBITDA of ₹8.64 Cr (EBITDA margin 11.4%). The net worth stands at ₹58.08 Cr (up 8.4% YoY). Total assets are valued at ₹67.22 Cr (up 13.2% YoY).
The company has about 492 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Mercury Laboratories. As per MCA filings, the company has open charges of ₹35.71 Cr and satisfied charges of ₹33.61 Cr on record. Court records list 71 cases involving the company, including 40 filed by the company and 31 filed against it; 13 cases are pending. The company has 1 deal on record (1 market trade); the latest was in May 2023. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Asence Pharma Private Limited with revenue of ₹77.56 Cr. The company has 5 MSME Form 1 returns on record between 2019 and 2021, listing 616 overdue payments to 33 micro and small suppliers.
Mercury Laboratories Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-24-0002899). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website mercurylabs.com.
Company details
CIN history
Mercury Laboratories has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74239MH1982PLC026341, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L74239MH1982PLC026341 | Current |
| U74239MH1982PTC026341 | Previous |
| U74239MH1982PLC026341 | Previous |
Recognitions & Rankings of Mercury Laboratories
Contact details
Mercury Laboratories Limited's registered office is in Mumbai, Maharashtra. Its website is mercurylabs.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressShreeji Mang Idas Marketprincess Street, Mumbai, Maharashtra, India – 400002
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Mercury Laboratories Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Mercury Laboratories operates one associated brand: Mercury Laboratories. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical drugs are manufactured by Mercury Laboratories in India. | mercurylabs.com |
Business activity
The main business activity of Mercury Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Mercury Laboratories Limited, buy the company report.
Financials of Mercury Laboratories Limited
FY 2025-26 filings availableMercury Laboratories Limited reported revenue of ₹75.94 Cr (up 1.1% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 75.94 | 75.10 | 75.56 | 75.33 | 57.92 | 68.60 | 57.27 |
| Revenue growth | +1.1% | -0.6% | +0.3% | +30.1% | -15.6% | +19.8% | - |
| EBITDA | 8.64 | 7.02 | 9.02 | 8.58 | 6.98 | 9.59 | 6.16 |
| EBITDA margin | +11.4% | +9.4% | +11.9% | +11.4% | +12.1% | +14.0% | +10.8% |
| Profit before tax | 6.64 | 4.66 | 6.91 | 7.46 | 5.02 | 7.91 | 4.32 |
| Net profit | 5.14 | 3.07 | 5.59 | 5.62 | 3.44 | 5.34 | 3.22 |
| Net profit margin | +6.8% | +4.1% | +7.4% | +7.5% | +5.9% | +7.8% | +5.6% |
| EPS (₹) | 40.28 | 26.21 | 47.12 | 46.49 | 29.68 | 44.48 | 26.90 |
| Balance sheet | |||||||
| Total assets | 67.22 | 59.40 | 56.70 | 51.46 | 47.54 | 45.27 | 40.36 |
| Net worth | 58.08 | 53.57 | 50.84 | 45.63 | 40.31 | 36.89 | 31.98 |
| Total debt | 8.43 | 5.45 | 5.55 | 5.83 | 5.99 | 7.10 | 7.19 |
| Cash & bank | 6.18 | 2.19 | 8.23 | 7.32 | 6.93 | 4.87 | 2.51 |
| Net working capital | 34.65 | 25.80 | 29.85 | 28.67 | 22.54 | 19.83 | 17.32 |
| Cash flow | |||||||
| Cash from operations | 4.24 | 4.86 | 8.23 | 2.45 | 5.19 | 8.21 | 5.49 |
| Cash from investing | (3.17) | (9.04) | (6.27) | (1.06) | (1.89) | (4.62) | (1.14) |
| Cash from financing | 2.91 | (1.85) | (1.04) | (1.01) | (1.23) | (1.24) | (3.33) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19.01 | 15.96 | 20.44 | 18.35 | 19.01 | 18.14 | 20.66 | 19.57 |
| Revenue growth (YoY) | 0.0% | -12.0% | -1.1% | -6.2% | +4.5% | +8.8% | - | - |
| Other income | 0.38 | 0.05 | 0.67 | 0.31 | 0.79 | 0.18 | 0.18 | 0.53 |
| Total expenses | 17.57 | 14.77 | 18.40 | 16.23 | 16.88 | 15.78 | 18.54 | 17.60 |
| EBITDA | 1.44 | 1.19 | 2.04 | 2.12 | 2.13 | 2.36 | 2.12 | 1.97 |
| EBITDA margin | +7.6% | +7.5% | +10.0% | +11.6% | +11.2% | +13.0% | +10.3% | +10.1% |
| Depreciation | 0.74 | 0.73 | 0.84 | 0.87 | 0.86 | 0.84 | 0.73 | 0.74 |
| Interest | 0.16 | 0.12 | 0.13 | 0.14 | 0.13 | 0.15 | 0.13 | 0.13 |
| Profit before tax | 0.92 | 0.39 | 1.74 | 1.42 | 1.93 | 1.55 | 1.44 | 1.63 |
| Tax | 0.24 | 0.09 | 0.51 | 0.44 | 0.28 | 0.58 | 0.34 | 0.45 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19.01 | 15.96 | 20.44 | 18.35 | 19.01 | 18.14 | 20.66 | 19.57 |
| Revenue growth (YoY) | 0.0% | -12.0% | -1.1% | -6.2% | +4.5% | +8.8% | - | - |
| Other income | 0.38 | 0.05 | 0.67 | 0.31 | 0.79 | 0.18 | 0.18 | 0.53 |
| Total expenses | 17.57 | 14.77 | 18.40 | 16.23 | 16.88 | 15.78 | 18.54 | 17.60 |
| EBITDA | 1.44 | 1.19 | 2.04 | 2.12 | 2.13 | 2.36 | 2.12 | 1.97 |
| EBITDA margin | +7.6% | +7.5% | +10.0% | +11.6% | +11.2% | +13.0% | +10.3% | +10.1% |
| Depreciation | 0.74 | 0.73 | 0.84 | 0.87 | 0.86 | 0.84 | 0.73 | 0.74 |
| Interest | 0.16 | 0.12 | 0.13 | 0.14 | 0.13 | 0.15 | 0.13 | 0.13 |
| Profit before tax | 0.92 | 0.39 | 1.74 | 1.42 | 1.93 | 1.55 | 1.44 | 1.63 |
| Tax | 0.24 | 0.09 | 0.51 | 0.44 | 0.28 | 0.58 | 0.34 | 0.45 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 75.94 | 75.10 | 75.56 | 75.33 | 57.92 | 68.60 | 57.27 |
| Revenue growth | +1.1% | -0.6% | +0.3% | +30.1% | -15.6% | +19.8% | - |
| Other income | 1.96 | 1.07 | 1.09 | 1.72 | 0.94 | 0.88 | 0.85 |
| Total expenses | 67.30 | 68.08 | 66.54 | 66.75 | 50.94 | 59.01 | 51.11 |
| Employee cost | 17.44 | 16.84 | 14.50 | 14.24 | 12.50 | 9.80 | 9.30 |
| EBITDA | 8.64 | 7.02 | 9.02 | 8.58 | 6.98 | 9.59 | 6.16 |
| EBITDA margin | +11.4% | +9.4% | +11.9% | +11.4% | +12.1% | +14.0% | +10.8% |
| Depreciation | 3.42 | 2.88 | 2.82 | 2.48 | 2.45 | 1.92 | 1.87 |
| Interest | 0.54 | 0.55 | 0.38 | 0.36 | 0.45 | 0.64 | 0.82 |
| Profit before tax | 6.64 | 4.66 | 6.91 | 7.46 | 5.02 | 7.91 | 4.32 |
| Tax | 1.80 | 1.52 | 1.27 | 1.86 | 1.47 | 2.57 | 1.10 |
| Net profit | 5.14 | 3.07 | 5.59 | 5.62 | 3.44 | 5.34 | 3.22 |
| Net profit margin | +6.8% | +4.1% | +7.4% | +7.5% | +5.9% | +7.8% | +5.6% |
| EPS (₹) | 40.28 | 26.21 | 47.12 | 46.49 | 29.68 | 44.48 | 26.90 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 |
| Reserves & surplus | 56.88 | 52.37 | 49.64 | 44.43 | 39.11 | 35.69 | 30.78 |
| Shareholders' funds (net worth) | 58.08 | 53.57 | 50.84 | 45.63 | 40.31 | 36.89 | 31.98 |
| Secured loans | 4.22 | 1.67 | 3.07 | 2.94 | 2.72 | 4.58 | 3.43 |
| Unsecured loans | 4.21 | 3.78 | 2.48 | 2.89 | 3.27 | 2.52 | 3.76 |
| Total debt | 8.43 | 5.45 | 5.55 | 5.83 | 5.99 | 7.10 | 7.19 |
| Total liabilities | 67.22 | 59.40 | 56.70 | 51.46 | 47.54 | 45.27 | 40.36 |
| Assets | |||||||
| Gross block | 50.99 | 48.32 | 45.68 | 43.96 | 43.04 | 41.18 | 36.58 |
| Net block | 23.89 | 24.64 | 24.03 | 24.26 | 25.82 | 26.36 | 23.66 |
| Capital work in progress | 9.82 | 9.32 | 3.82 | 0.13 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Inventories | 7.12 | 7.21 | 6.21 | 6.90 | 6.78 | 5.16 | 5.51 |
| Sundry debtors | 25.85 | 25.74 | 21.85 | 21.37 | 16.74 | 22.54 | 18.14 |
| Cash & bank balances | 6.18 | 2.19 | 8.23 | 7.32 | 6.93 | 4.87 | 2.51 |
| Loans & advances | 5.79 | 4.08 | 3.55 | 3.88 | 4.76 | 5.23 | 5.36 |
| Total current assets | 44.94 | 39.22 | 39.84 | 39.47 | 35.21 | 37.80 | 31.52 |
| Total current liabilities | 10.29 | 13.42 | 9.99 | 10.80 | 12.67 | 17.97 | 14.20 |
| Net working capital | 34.65 | 25.80 | 29.85 | 28.67 | 22.54 | 19.83 | 17.32 |
| Total assets | 67.22 | 59.40 | 56.70 | 51.46 | 47.54 | 45.27 | 40.36 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.19 | 8.23 | 7.32 | 6.93 | 4.87 | 2.51 | 1.48 |
| Net cash from operating activities | 4.24 | 4.86 | 8.23 | 2.45 | 5.19 | 8.21 | 5.49 |
| Net cash from investing activities | (3.17) | (9.04) | (6.27) | (1.06) | (1.89) | (4.62) | (1.14) |
| Net cash from financing activities | 2.91 | (1.85) | (1.04) | (1.01) | (1.23) | (1.24) | (3.33) |
| Net change in cash | 3.99 | (6.03) | 0.91 | 0.38 | 2.07 | 2.36 | 1.02 |
| Closing cash | 6.18 | 2.19 | 8.23 | 7.32 | 6.93 | 4.87 | 2.51 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +1.1% | -0.6% | +0.3% | +30.1% | -15.6% | +19.8% | - |
| EBITDA growth | +23.1% | -22.2% | +5.1% | +22.9% | -27.2% | +55.7% | - |
| PBT growth | +42.5% | -32.6% | -7.4% | +48.6% | -36.5% | +83.1% | +6.9% |
| Net income growth | +67.4% | -45.1% | -0.5% | +63.4% | -35.6% | +65.8% | - |
| Revenue CAGR (3Y) | +0.3% | +9.0% | +3.3% | +9.6% | +1.4% | +9.8% | +6.1% |
| EBITDA CAGR (3Y) | +0.2% | +0.2% | -2.0% | +11.7% | +6.9% | +29.7% | -2.9% |
| Profitability & leverage | |||||||
| Net income margin | +6.4% | +4.2% | +7.5% | +7.4% | +6.1% | +7.8% | +5.6% |
| Return on capital employed | +11.3% | +9.0% | +13.5% | +15.8% | +11.8% | +20.0% | +12.9% |
| Return on net worth | +8.7% | +6.0% | +11.7% | +13.0% | +9.2% | +15.5% | +10.6% |
| Debt / equity | 0.12 | 0.11 | 0.12 | 0.14 | 0.17 | 0.21 | 0.27 |
| Long-term debt / equity | 0.10 | 0.06 | 0.06 | 0.06 | 0.12 | 0.18 | 0.22 |
| Interest cover | 10.34 | 13.29 | 6.13 | 5.90 | 9.93 | 8.34 | 19.11 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.53 | 1.60 | 1.69 | 1.73 | 1.38 | 1.76 | 1.59 |
| Inventory turnover | 10.60 | 11.19 | 11.53 | 11.01 | 9.70 | 12.86 | 9.32 |
| Debtors turnover | 2.94 | 3.16 | 3.50 | 3.95 | 2.95 | 3.37 | 3.06 |
| EPS (₹) | 40.28 | 26.21 | 47.12 | 46.49 | 29.68 | 44.48 | 26.90 |
| Dividend per share (₹) | 3.50 | 3.50 | 3.50 | 3.50 | 3.50 | 3.50 | 2.00 |
| Book value per share (₹) | 483.97 | 446.41 | 423.65 | 380.24 | 335.89 | 307.45 | 266.48 |
To see the full year-wise statements and ratios of Mercury Laboratories Limited, buy the company report.
Board of directors of Mercury Laboratories Limited
Mercury Laboratories has 6 current directors and 14 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rajendrakumar Ramanlal Shah | Managing Director | 16 Feb 1982 | 44 Years 9 Months | Current |
| Paresh Jagdishbhai Mistry | Director | 01 Oct 2017 | 9 Years 1 Months | Current |
| Dilip Ramanlal Shah | Director | 16 Feb 1982 | 44 Years 9 Months | Current |
| Janki Rajendra Shah Also directs: Mercury Antibiotics LLP | Director | 05 Feb 2020 | 6 Years 9 Months | Current |
| Sanjay Patel Also directs: Ace Blue Ventures LLP, Aromix Private Limited, Multidimensional Holdings and Consultants Private Limited and 3 more | Director | 14 May 2025 | 1 Years 6 Months | Current |
| Jayantilal Dhaneshwar Raval | Director | 24 Jul 2024 | 2 Years 3 Months | Current |
Peer comparison
Mercury Laboratories Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Asence Pharma Private Limited | ₹77.56 Cr (FY 2025) | 19.0% | Vadodara, Gujarat, India | |||
| Vasa Pharma Chem Pvt Ltd | ₹77.38 Cr (FY 2025) | -8.0% | Ahmedabad, Gujarat, India | |||
| Vapi Care Pharma Private Limited | ₹76.81 Cr (FY 2025) | -11.0% | Vapi, Valsad, Gujarat, India | |||
| Eskag Pharma Pvt Ltd | ₹76.72 Cr (FY 2024) | 0.0% | Kolkata, West Bengal, India | |||
| Vovantis Laboratories Private Limited | ₹76.05 Cr (FY 2025) | 67.0% | Vadodara, Gujarat, India | |||
| Higlance Laboratories Private Limited | ₹75.98 Cr (FY 2025) | 7.0% | New Delhi, Delhi, India | |||
| Vital Therapeutics and Formulations Private Limited | ₹75.96 Cr (FY 2024) | 2.0% | Hyderabad, Telangana, India | |||
| Mercury Laboratories Limitedthis company | ₹75.94 Cr (FY 2026) | ₹5.14 Cr | 6.8% | 1.1% | 492 | Mumbai, Maharashtra, India |
| Bennet Pharmaceuticals Limited | ₹75.82 Cr (FY 2025) | 11.0% | Vadodara, Gujarat, India |
To see the full peer comparison of Mercury Laboratories Limited, buy the company report.
Auditor
Mercury Laboratories Limited is audited by NARESH AND CO for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| NARESH AND CO | FY 2025 | 106928W |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 73.70%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 26.30%.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 73.70% | 73.70% | 73.70% | 73.70% |
| Public | 26.30% | 26.30% | 26.30% | 26.30% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 06 Mar 2026 | 101257925 | Sidbi | ₹18 Cr | Open | |
| 19 Dec 2024 | 101022958 | Sidbi | ₹1.9 Cr | Open | |
| 14 Mar 2024 | 100886860 | Hdfc Bank Limited | ₹20 Lakh | Open | |
| 25 May 2023 | 100723959 | Hdfc Bank Limited | ₹50 Lakh | Open | |
| 27 Sep 2021 | 100500033 | Hdfc Bank Limited | ₹7.06 Cr | Open |
To see the full charge records of Mercury Laboratories Limited, buy the company report.
Total charge records: 19 View all charges
Deals & funding
Mercury Laboratories Limited has 1 deal on record (1 market trade); the latest was in May 2023.
Deals on record (1 of 1)
| When | Deal | Amount | Parties |
|---|---|---|---|
| May 2023 | Market trade | ₹1.55 Cr | Buyer: an individual Seller: an individual |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Mercury Laboratories Limited has 71 court cases on record: 40 filed by Mercury Laboratories, 31 filed against it. 13 cases are pending and 58 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 41 | 25 | 9 |
| High courts | 29 | 5 | 4 |
| Supreme Court | 1 | 1 | 0 |
Cases on record (5 of 71)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Kerala | Writ petition | Filed by the company against Kerala Medical Services Corporation Ltd. and 1 other | Disposed |
| High Court, Kerala | Court case (AR) | Filed by the company against Kerala Medical Service Corporation Limited Thycaud and 1 other | Disposed |
| High Court | Writ petition | Filed by the company against Kerala Medical Services Corporation Ltd and 1 other | Disposed |
| High Court, GUJARAT | Special civil application | Filed by the company against Mercury Phytochem Ltd., and 4 others | Disposed |
| District court, Vadodara, Gujarat | Court case (SPCS) | Filed by the company against Asoj Soft Caps Pvt.Ltd. | Disposed |
To see the full case history of Mercury Laboratories Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Mercury Laboratories Limited has 5 MSME Form 1 returns on record between 2019 and 2021, listing 616 overdue payments to 33 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 33)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Mercury Laboratories Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Mercury Laboratories Limited has a workforce of 492 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 492 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 | |
| FY 2015-16 | |
| FY 2014-15 |
To see the full employee and EPFO history of Mercury Laboratories Limited, buy the company report.
GST
Mercury Laboratories has 10 GST registrations: 8 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACM0414D2Z5 | Maharashtra | Active | 14 Dec 2017 |
| 09AAACM0414D1Z4 | Uttar Pradesh | Active | 01 Jul 2017 |
| 24AAACM0414D1ZC | Gujarat | Active | 01 Jul 2017 |
| 33AAACM0414D1ZD | Tamil Nadu | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Mercury Laboratories Limited, buy the company report.
Recent activity
Mercury Laboratories Limited has 24 board changes on record since 1982: 15 appointments and 9 cessations. The latest: Bharat Dhirajlal Mehta ceased to be Director on 14 May 2025.
56 earlier events are in the company report.
News
Frequently asked questions
Mercury Laboratories is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 12 February 1982 (44+ years old) and is registered under CIN L74239MH1982PLC026341. Listed on BSE: 538964.
Mercury Laboratories reported revenue of ₹75.94 Cr for FY 2025-26 (up 1.1% YoY) based on standalone financials.
Mercury Laboratories has 6 current directors:
- Rajendrakumar Ramanlal Shah - Managing Director
- Paresh Jagdishbhai Mistry - Director
- Dilip Ramanlal Shah - Director
- Janki Rajendra Shah - Director
- Sanjay Patel - Director
- Jayantilal Dhaneshwar Raval - Director
The latest financial statements of Mercury Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 13 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Mercury Laboratories is 27AAACM0414D2Z5, registered in Maharashtra. The company has 10 GST registrations in all, of which 8 are active and 2 are cancelled or inactive. Other active GSTINs include 09AAACM0414D1Z4 (Uttar Pradesh), 24AAACM0414D1ZC (Gujarat), 33AAACM0414D1ZD (Tamil Nadu).
The CIN (Corporate Identification Number) of Mercury Laboratories is L74239MH1982PLC026341. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Mercury Laboratories is a listed company as per MCA records. Its shares are listed on BSE (code: 538964).
Mercury Laboratories has 71 court cases on record: 40 filed by the company and 31 filed against it. 13 are pending. Most are in the district courts.
Mercury Laboratories was incorporated on 12 February 1982, making it 44+ years old. It is registered with the Registrar of Companies, Mumbai.
Mercury Laboratories has 1 deal on record (1 market trade); the latest was in May 2023.
The peers of Mercury Laboratories by revenue are Asence Pharma Private Limited, Vasa Pharma Chem Pvt Ltd, Vapi Care Pharma Private Limited, Eskag Pharma Pvt Ltd, Vovantis Laboratories Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Bharat Dhirajlal Mehta ceased to be Director on 14 May 2025. Sanjay Patel was appointed as Director on 14 May 2025. Divyakant Ramniklal Zaveri ceased to be Director on 25 Jul 2024. Mercury Laboratories has 24 board changes on record in total.

